Natera's Cancer Test Wins Landmark NCCN Backing, Reshaping Oncology

AUSTIN, TX – June 23, 2026 – In a move that reverberates through the halls of oncology clinics and the trading floors of Wall Street, the National Comprehensive Cancer Network® (NCCN®) has fundamentally altered the treatment landscape for muscle-invasive bladder cancer (MIBC). The influential organization has updated its clinical practice guidelines to recommend the use of personalized, circulating tumor DNA (ctDNA) testing to guide treatment—a decision that catapults Natera, Inc.'s Signatera™ test to the forefront of precision medicine.

This is not a minor tweak to a medical manual. It represents a watershed moment, validating a technology that promises to shift cancer care from a standardized protocol to a deeply personalized strategy. For the first time, the NCCN has given its highest-level endorsement to using a molecular residual disease (MRD) test to make critical decisions about postsurgical therapy, signaling the maturation of liquid biopsy technology from a promising research tool to an indispensable clinical instrument.

A New Standard of Care Emerges

The updated NCCN guidelines for bladder cancer now recommend considering ctDNA-MRD testing to stratify risk and decide on the use of adjuvant immunotherapy after a cystectomy (bladder removal surgery). The recommendation specifically points to "an FDA-approved, personalized, tumor-informed, multiplex PCR-NGS assay," a detailed description that currently applies squarely to Natera's Signatera.

Crucially, the guidelines include a Category 1 recommendation for using Signatera to guide treatment with the immunotherapy drug atezolizumab. A Category 1 designation is the NCCN's strongest endorsement, reserved for interventions backed by high-level evidence from Phase 3 randomized clinical trials. It effectively establishes a new standard of care, telling oncologists that there is uniform consensus on the appropriateness of this approach.

“This guideline update marks an important turning point for patients with muscle-invasive bladder cancer,” said Matthew D. Galsky, M.D., a leading oncologist and deputy director of the Mount Sinai Tisch Cancer Center. “For the first time, NCCN has incorporated ctDNA-MRD testing into clinical decision-making following cystectomy. These recommendations are supported by prospective phase 3 evidence showing that a ctDNA-guided approach, using Signatera, can help guide post-surgical treatment decisions.”

The clinical implications are profound. After surgery, the central question for MIBC patients and their doctors is whether to administer additional (adjuvant) therapy to eliminate any microscopic cancer cells left behind and prevent recurrence. This has always been a challenging decision, balancing the potential benefit against the toxicity and cost of treatment. The new guideline provides a powerful tool to resolve this dilemma. Patients who test positive for MRD via Signatera are identified as being at high risk of recurrence and are now strongly recommended for immunotherapy. Conversely, patients who test negative have an excellent prognosis, allowing clinicians to confidently recommend observation and spare them from potentially unnecessary and debilitating treatments.

The Science of a Practice-Changing Trial

The NCCN's decision did not occur in a vacuum. It is the direct result of robust evidence from the landmark IMvigor011 clinical trial, a study whose design and results showcase the power of precision diagnostics. The Phase 3 trial, sponsored by Genentech, was specifically designed to test a ctDNA-guided strategy using the Signatera assay.

The trial's origins trace back to a previous study, IMvigor010, which failed to show a benefit for adjuvant atezolizumab in an unselected MIBC population. However, a retrospective analysis of that trial revealed a critical insight: a subset of patients who were ctDNA-positive did appear to benefit. This hypothesis was then prospectively tested in IMvigor011. Patients who had undergone surgery were monitored with Signatera; those who tested positive for MRD were then randomized to receive either atezolizumab or a placebo.

The results, presented at a major medical conference and published in The New England Journal of Medicine, were definitive. The ctDNA-positive patients who received atezolizumab showed statistically significant and clinically meaningful improvements in both disease-free survival and overall survival compared to those who received a placebo. Meanwhile, patients who remained ctDNA-negative had exceptional outcomes without any further treatment, confirming their low-risk status.

Signatera’s technological approach was key to this success. It is a "tumor-informed" assay, meaning it is custom-built for each patient. The process begins by sequencing the patient's original tumor tissue to identify a unique set of up to 16 cancer-specific mutations. The test then uses an ultra-sensitive method to search for traces of these exact mutations in the patient's blood. This personalized approach provides a highly accurate and specific signal of residual cancer, far more sensitive than traditional imaging methods like CT scans, which can only detect tumors once they have grown to a considerable size.

Market Validation and Natera's Ascent

For Natera, this NCCN endorsement is the culmination of years of strategic investment and clinical evidence generation. It follows a May 2026 U.S. Food and Drug Administration (FDA) approval for Signatera as a companion diagnostic to identify MIBC patients who may benefit from atezolizumab. The combination of FDA approval and a Category 1 NCCN recommendation creates a powerful moat, solidifying the company's dominant position in the burgeoning MRD market.

"These recommendations reflect years of work to generate the clinical evidence establishing MRD as a clinically actionable and predictive tool,” said Kevin Masukawa, Ph.D., a vice president at Natera. “The IMvigor011 study is an important example of how Signatera-generated evidence can help change clinical practice, and we believe this guideline update is just the beginning of a broader shift toward MRD-guided cancer care.”

This "broader shift" is already underway. While competitors like Guardant Health are also major players in the liquid biopsy space, Natera's successful execution of a trial designed specifically to support a ctDNA-guided treatment paradigm in MIBC gives it a significant first-mover advantage in this indication. The specificity of the NCCN's language—calling for an "FDA-approved, personalized, tumor-informed" test—directly points to Signatera and sets a high bar for competitors.

The financial markets have taken note. With existing Medicare coverage for Signatera in MIBC and a growing list of commercial payers coming on board, the path to widespread reimbursement and adoption is clear. Analysts have lauded the move as a major catalyst for Natera, which has already been reporting explosive growth in its oncology division. The company's ability to successfully navigate the complex path from scientific innovation to clinical validation, regulatory approval, and now, inclusion in top-tier clinical guidelines, serves as a case study in building a durable diagnostics franchise. This isn't just about one test for one cancer; it's about establishing a platform and a methodology that can be replicated across numerous other solid tumors, promising a long runway for growth and a profound impact on how cancer is managed for years to come.